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Toll-like receptor 9 and the inflammatory
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Abstract
Objectives: Cardiac surgery can lead to post-operative end-organ complications secondary to activation of
systemic inflammatory response. We hypothesize that surgical trauma or cardiopulmonary bypass (CPB) may initiate
systemic inflammatory response via release of mitochondrial DNA (mtDNA) signaling Toll-like receptor 9 (TLR9) and
interleukin-6 production (IL-6).
Materials and methods: The role of TLR9 in systemic inflammatory response in cardiac surgery was studied using
a murine model of sternotomy and a porcine model of sternotomy and CPB. mtDNA and IL-6 were measured with
and without TLR9-antagonist treatment. To study ischemia-reperfusion injury, we utilized an ex-vivo porcine kidney
model.
Results: In the rodent model (n = 15), circulating mtDNA increased 19-fold (19.29 ± 3.31, p < 0.001) and plasma IL-6
levels increased 59-fold (59.06 ± 14.98) at 1-min post-sternotomy compared to pre-sternotomy. In the murine model
(n = 11), administration of TLR-9 antagonists lowered IL-6 expression post-sternotomy when compared to controls
(59.06 ± 14.98 vs. 5.25 ± 1.08) indicating that TLR-9 is a positive regulator of IL-6 after sternotomy. Using porcine
models (n = 10), a significant increase in circulating mtDNA was observed after CPB (Fold change 29.9 ± 4.8, p =
0.005) and along with IL-6 following renal ischaemia-reperfusion. Addition of the antioxidant sulforaphane reduced
circulating mtDNA when compared to controls (FC 7.36 ± 0.61 vs. 32.0 ± 4.17 at 60 min post-CPB).
Conclusion: CPB, surgical trauma and ischemic perfusion injury trigger the release of circulating mtDNA that
activates TLR-9, in turn stimulating a release of IL-6. Therefore, TLR-9 antagonists may attenuate this response and
may provide a future therapeutic target whereby the systemic inflammatory response to cardiac surgery may be
manipulated to improve clinical outcomes.
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Introduction
Cardiac surgery with the use of cardiopulmonary by-
pass (CPB) has been associated with a systemic in-
flammatory response potentially leading to significant
morbidity and mortality. This response is multi-
factorial involving the exposure of circulating blood
to artificial surfaces of the extracorporeal circuit, non-
physiological shear stress of the CPB roller pump,
hypothermia, and a potentially inevitable ischemia-
reperfusion injury (IRI) [1, 2]. The subsequent activa-
tion of a series of inflammatory cascades [3] can be
both further initiated and exacerbated by significant
tissue injury incurred during CPB, and worsened by
the release of endogenous inflammatory mediators [4].
The clinical sequelae of such a pro-inflammatory state
result in a hyper-dynamic circulation, increase in the
cardiac output and decrease in the systemic vascular
resistance, prompting the need for inotropic and
vasoconstrictive support [5]. Despite several significant
improvements in the CPB circuit such as heparin
coated circuit, the complications secondary to tissue
damage and inflammatory response still remain, and
can have a profound impact on post-operative out-
comes [6].
Toll like receptors are a superfamily of pattern recog-
nition receptors, a class of proteins acting as first-line in
the defense against pathogens. These proteins act to
recognize both pathogen-associated and damage-
associated molecular patterns (DAMPs), playing a sig-
nificant role in inflammation, cell immune regulation
and proliferation [7, 8]. Sources of DAMPs in sterile in-
flammation can be found in the mitochondrion, specific-
ally the mitochondrial DNA (mtDNA), which also
contains CpG-DNA repeats [9, 10]. During mechanical
injury or ischemia, necrosis and/or cellular apoptosis ul-
timately results in mitochondrial damage and leak of
mitochondrial contents into the bloodstream [9, 11, 12].
This leads to the potential signaling of TLR9, which rec-
ognizes unmethylated CpG sequences in DNA molecules
[13]. As such, TLR signaling provides a potential path-
way by which the inflammatory response to CPB may be
mediated, and a better understanding of this relationship
may in future enable us to provide a translational benefit
in clinical outcomes.
Primary cardiac surgical trauma, CPB and ischaemia
reperfusion injury (IRI) may all initiate the systemic in-
flammatory response. In this manuscript we aim to sys-
tematically address these mechanisms by examining the
release of mtDNA and determining TLR9 as an effector
of IL-6 expression. Finally, we evaluate the role of pre-
treatment with the anti-inflammatory and anti-oxidant
substance sulforaphane, as a means of dampening the in-
flammatory response in vitro with view to future transla-
tion into in vivo studies and subsequent clinical practice.
Material & Methods
In vitro model
Purification of total mtDNA
In all animal models, DNA Purification from Blood or
Body Fluids was performed using the QIAamp DNA
Blood Mini Kit (Qiagen®) according to the manufacturer
protocol [14]. In summary, DNA was extracted from
200 μl of plasma and concentrated by double elution
with 50 μl AE buffer. To detect DNA purity for any pro-
tein contamination, the A260/280 ratio of the DNA was
assessed using the NanoDrop® spectrophotometer, which
was between 1.7–1.9 excluding any contamination.
Quantitative real-time polymerase chain reaction (RT-
qPCR) was used to measure mtDNA levels using
primers that recognized the mitochondrial gene cyto-
chrome C oxidase subunit III in rat, mouse or pig
(Table 1). The reaction was prepared using 1 μl of DNA
in each tested well plus 12.5 μl of SYBR Green PCR
Master Mix (Taqman, Applied Biosystems, Life Tech-
nologies, Paisley, UK), 0.5 μl of mtDNA primer and
10.5 μl of water. For each study probe identical RT-
qPCR reactions were also carried out using a sterile
water negative control and a HUVEC mtDNA positive
control.
All reactions were carried out in three technical repli-
cates using the Applied Biosystems 7500 fast Real-Time
PCR System [15]. Amplification plots were examined for
adequate amplification and successful PCR reaction.
Table 1 Quantitative real-time polymerase chain reaction (RT-qPCR) primers used in small and large animal models
Gene Specific Primer Forward Reverse
Mouse
Interleukin-6 CCTCTGGTCTTCTGGAGTACC ACTCCTTCTGTGACTCCAGC
Cytochrome oxidase C AAAGTTGAACTGTACCCCTTAAGT CACTCATTTGTGCTCCTGTTCATC
Rodent
Cytochrome oxidase C ACATACCAAGGCCACCAAC CAGAAAAATCCGGCAAAGAA
Pig
Cytochrome oxidase C CCCATTATGATTGGGGGTTT TGCTGTGTATGCGTCAGGAT
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Animal models
All animals received humane care in compliance with
the Principles of Laboratory Animal Care and according
to UK Home Office regulations and approved by local
ethical Central Ethical Review Process Committee
known as Animal Welfare and Ethical Review Body
(AWERB).
Rat model
Adult male Sprague–Dawley rats (n = 15) (400-450 g)
were acclimatized prior to study and housed in individu-
ally ventilated cages with no more than 3 per cage for 2
weeks. During the procedure the rats were anaesthetized
using intraperitoneal ketamine (50 mg/kg) and xylazin
(2mg/kg), tracheostomy and endotracheal intubation with
14G cannula and mechanical ventilation for 15–20min.
At the end of the experiment, the animals were eutha-
nized using intravenous barbiturate overdose. To detect
the circulating level of the mtDNA through mimicking
the cardiac surgical access, midline sternotomy was per-
formed where initially the skin was shaved then 2 cm mid-
line skin incision above the sternal was performed and
gentle dissection of subcutaneous tissue and lifting the
sternum with forceps and using scissors to perform the
sternotomy, care was taken to preserve the pleura to avoid
pneumothorax. Tail vein blood samples were collected
separately at pre-sternotomy and 1- and 10-min post-
sternotomy.
Mouse model- response to TLR9 suppression with ODN2088
Eleven male C57BL/6, 9–10-week-old mice (6 control; 5
experimental) were acclimatized prior to the study and
housed in individually ventilated cages with no more
than 4 mice per cage for 2 weeks. Test mice were
injected with intra-peritoneal mouse-preferred synthetic
TLR-9 antagonist oligodeoxynucleotide ODN2088 (Invi-
voGene®, San Diego, CA, USA) (100 μg/25 g body
weight) prior to induction of anesthesia. An equal vol-
ume of 0.9% saline was used for the control group. Mice
were anaesthetized using ketamine (50 mg/kg) and xyla-
zin (2 mg/kg) and intubation was done through neck in-
cision. Shaving skin then 1 cm midline skin incision
above the sternal was performed and gentle dissection of
subcutaneous tissue and lifting the sternum with forceps
and using scissors to perform the mid line sternotomy,
care was taken to preserve the pleura to avoid pneumo-
thorax. Two pre-sternotomy blood samples were col-
lected, before and after intubation. A third sample was
taken immediately after sternotomy. At the end of the
experiment, euthanasia was done by cervical dislocation.
Large animal porcine model
In the large animal setting we proceeded with perform-
ing CPB with the same bypass circuit systems that are
used in humans using Stöckert multiflow roller pump
(Sorin Group GmbH, Munich, Germany). Surgical ap-
proach was through midline sternotomy using a Gigli
saw, standard systemic heparinization was performed
(300 IU/kg) achieving activated clotting time (ACT)
greater than 400 s. CPB arterial cannulation was per-
formed through ascending aortic when ACT> 400 s. The
venous drainage was through right atrial cannulation
using two-stage venous cannula, directing the distal end
towards the inferior vena cava. Non-pulsatile CPB was
subsequently maintained under normal pigs’
temperature (38-39C°) for 2 h with flow of 2 to 4 L/min
and line pressure < 300 mmHg with disconnected lung
ventilation.
In the first part of the experiment was to test the effect
of circulating mtDNA in pigs in relation to CPB. Total
of ten pigs underwent median sternotomy (represented
by pre-CPB time point), half had CPB (n = 5) and half
sham mechanically ventilated pigs underwent median
sternotomy alone (n = 5). Five ml blood sampling was
taken at different time-points in relation to CPB com-
mencement (pre, end of CPB, and 90-min after CPB).
Second part of the experiment includes total of ten pigs
underwent CPB, half were pre-treated with 2 mg/kg anti-
oxidants sulforaphane (n = 5) versus normal saline (n =
5). Five ml blood sampling was performed at different
time-points in relation to CPB commencement (pre, at
onset of CPB, at 60-min and 120-min of CPB). Plasma
sample was separated by centrifugation of blood (10 min
at 3000 x g) and stored at − 80 °C until further process-
ing. The mtDNA was extracted and RT-qPCR was per-
formed as outlined above.
Antioxidant response
Ten female Landrace pigs (50–60 kg) were used accord-
ing to UK Home Office regulations and Directive 2010/
63/EU of the European Parliament and in compliance
with the Guide for the Care and Use of Laboratory Ani-
mals. Ketamine (20 mg/kg)/xyalzine (2 mg/kg) was used
for sedation prior to induction of anesthesia with 5% iso-
flurane, followed by standard endotracheal intubation.
Five pigs were then treated immediately with IV injec-
tion of Saline and the other 5 with IV sulforaphane (2
mg/kg) (the results in relation to sulforaphane in this
study were published by Nguyen et al. where the author
investigated the phosphorylation of p38 MAPK and NF-
kB in relation to antioxidant sulforaphane pre-
treatment) [16]. mtDNA was extracted from plasma as
per the previous experiment; RT-PCR was performed
using each samples in triplicate as described in 2.1.1.
Ischemia-reperfusion injury (IRI)
IRI was assessed in an ex-vivo renal reperfusion model.
Autologous whole blood and perfusate were used to
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simulate the cold ischemia prior to implantation,
followed by warm reperfusion. Where Warm ischemic
injury is sustained in the time between donor cardiac ar-
rest and organ removal. This is followed by further cold
ischemic damage that ensues after flushing and storage
of the allograft with cold preservation solution, and then
transport to the recipient center. This simulation closely
resembles the ischemia and reperfusion when the aorta
is cross-clamped and then released during CPB.
Thirteen porcine kidneys were retrieved from cadav-
eric pigs at an abattoir, flushed with cold storage Univer-
sity of Wisconsin (UW) solution and placed on ice for
transport back to the laboratory. Kidneys were then per-
fused on a modified Waters Medical (RM3) perfusion
machine at 4 °C with UW solution for 6-h and then
underwent autologous whole blood normothermic per-
fusion for 6-h. Perfusate samples during hypothermic
and normothermic perfusion will be collected for deter-
mination of damage biomarkers. DNA was extracted
from plasma at different time-points of reperfusion (pre,
5-min, 20-min, 2-h, 4-h and 6-h). RT-PCR with cyto-
chrome C mitochondrial primer was employed to detect
the level of circulating mtDNA. IL-6 was measured as
previously described.
Statistical analysis
Statistical analysis was conducted using GraphPad Prism
version 8.1.2. Results are expressed as means ± SE at
each time point for each group, P-values < 0.050 were
considered statistically significant. Due to the nature of
the experiments with small number of animals, non-
parametric comparative analysis was used. Wilcoxon
signed rank tests were used for matched pairs and,
where relevant, p values were adjusted for multiple-
comparison using Bonferroni correction methodology.
For comparisons with more than 2 groups, Friedman
test was used with correction for multiple comparison
employed using Dunn’s methodology.
Results
Sternotomy enhanced circulating mtDNA in a rodent
model
Circulating mtDNA demonstrated a significant 19-fold
increase immediately post sternotomy (At 1-min: FC
19.29 ± 3.31; p < 0.001). At 10 min post-sternotomy,
mtDNA had fallen to FC 9.79 ± 1.61; but remained
statistically significant when compared to control
(p < 0.019), suggesting a significant response of
plasma mtDNA to surgical trauma (Fig. 1).
TLR9 antagonism reduced circulating IL-6 levels in
response to surgical induction in a murine model
Anesthesia and intubation resulted in an increase in IL-6
expression when compared to pre-induction levels in the
control (FC 25.8 ± 6.13) and the anti-TLR9 (FC 3.22 ±
0.68) animals; however, this increase was much lower in
the TLR9-antagonist group (Fig. 2).
A further increase in IL-6 expression was seen in both
groups after sternotomy, however this rise was again
dampened in the TLR9-antagonist group (FC 5.25 ± 1)
compared to control group (FC 59.06 ± 14.99) (Fig. 2).
These data indicate that TLR9 is a positive regulator of
IL-6 production in response to surgical trauma.
Sulforaphane reduced mtDNA release in response to
surgical trauma
In the porcine model, circulating mtDNA increased at
the end of CPB (FC 29.9 ± 4.79; p = 0.005) when
Fig. 1 Circulating mtDNA level in response to sternotomy in the rodent model. Plasma level of circulating mtDNA in the rodent model
undergoing median sternotomy at different time points. Circulating mtDNA levels peaked immediately after sternotomy
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compared to pre-operative levels, however this rise was
transient and had reduced by 90-min post-CPB when
compared to end of CPB levels (FC 6.47 ± 0.57, p = 0.34)
(Fig. 3). The sham group showed a minimal increase in
circulating mtDNA at the end of CPB time-point equiva-
lent (FC 1.68 ± 0.23, P = 0.17), followed by a further in-
crease at the 90-min post-CPB time-point equivalent
(2.41 ± 0.42, p = 0.013) compared to baseline (Fig. 3).
Both sulforaphane and non-sulforaphane groups
showed increases in circulating mtDNA levels at all
timepoints compared to pre-CPB levels. However, sulfo-
raphane significantly reduced the concentration of circu-
lating mtDNA at both 60- (FC 7.36 ± 0.61 vs. 32.0 ±
4.17) and 120- (FC 13.4 ± 1.2 vs. 49.9 ± 8.6) minutes after
CPB when compared to the non-sulforaphane group
(Fig. 4).
Ischemia-reperfusion injury
Circulating mtDNA showed a steady increase up to 4 h
after reperfusion in kidneys that were perfused ex vivo.
IL-6 also increased during reperfusion throughout the
study period. At 6 h after reperfusion, circulating
mtDNA levels began to decline whilst IL-6 remained sig-
nificantly elevated when compared to pre-perfusion
levels (Fig. 5).
Fig. 2 Level of circulating IL-6 in response to sternotomy in the murine model. Plasma level of IL-6 in the murine model undergoing median
sternotomy at different time-points with and without pre-treatment with TLR9-antagonist (ODN2088). The plasma level of IL-6 significantly
decreased when TLR9 blocked by OND2088
Fig. 3 Circulating mtDNA level in response to CPB in the porcine model. Plasma level of circulating mtDNA in the porcine model undergoing
median sternotomy with CPB at different time-points vs. sham
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Discussion
Cardiopulmonary bypass, surgical trauma and the associ-
ated ischemia-reperfusion injury (IRI) may all activate
the inflammatory response to cardiac surgery, potentially
causing significant morbidity [1, 17–20]. However, the
mechanisms involved are still not completely under-
stood. Mitochondrial damage associated proteins
(DAMPs) have been demonstrated as inflammatory
modulators leading to tissue damage in a variety of
pathological conditions including systemic inflammatory
Fig. 4 Effect of sulforaphane on mtDNA levels in CPB in the porcine model. Plasma levels of circulating mtDNA in the porcine CPB model at
different time-points with or without sulforaphane pre-treatment. There was significant reduction in mtDNA levels in response to
sulforaphane pre-treatment
Fig. 5 Effect of ischemic-perfusion on mtDNA nad IL-6 in porcine kidneys. Plasma level of circulating mtDNA and IL-6 in ex-vivo porcine kidney
model at different time points of IRI (Dotted lines represent mtDNA and solid lines represent IL-6). All data shown are mean ± SE (* = p < 0.05,
** = p < 0.001, ***p < 0.0001)
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response syndrome (SIRS), connective tissue diseases,
myocardial infarction, vascular dysfunction and in individ-
uals receiving chemotherapy and hemodialysis [21–23].
In this study we addressed the role of surgery-induced
mitochondrial damage in the downstream signaling of
the pro-inflammatory cytokine IL-6 via the TLR-9
pathway. We have confirmed the accumulation of mito-
chondrial DNA in the circulation using several in vivo
post-sternotomy/cardiopulmonary bypass models. Fur-
thermore, we have shown that blockade of TLR-9
in vivo results in a significant decrease in IL-6 expres-
sion thus revealing a direct relationship between TLR-9
signaling subsequent IL-6 driven inflammatory pathways
in surgical trauma.
Post-cardiac surgery, inflammation is thought to be re-
lated to a triad of surgical stimuli including CPB, surgi-
cal trauma and ischaemia-reperfusion. Addressing each
point in turn we demonstrate mitochondrial damage and
subsequent mtDNA release in all three components of
this triad. However, our results suggest these factors are
not equally weighted in driving inflammation, with
mtDNA release far more strongly related to CPB than
surgical trauma in our large animal model. Furthermore,
longer durations of CPB continued to drive mitochon-
drial damage, leading to an ongoing increase in mtDNA
release suggesting a correlation between overall bypass
time and the post-operative inflammatory response.
Some studies showed cardiac surgery with long-CPB
(> 100 min) has higher mtDNA levels than short-CPB
(< 100 min) [24].
It has been demonstrated that mtDNA activates neu-
trophils throughTLR9/p38 MAPK [10] and enhance
TLR9 expression in lung tissue in rats [25]. Our study
also confirms the relationship between mitochondrial
damage, as measured by circulating mtDNA release, and
the signaling of TLR9 in a controlled animal model.
TLR9 recognizes bacterial DNA motifs [13] and as
mtDNA has a similar molecular signature to bacterial
DNA this subsequently signals downstream TLR9 medi-
ated inflammatory pathways [26]. Recent studies have
now shown this remains true in humans, with an aver-
age 6-fold increase in circulating mtDNA observed fol-
lowing CPB when compared to pre-CPB levels in one
study [27]. Similarly, this work demonstrated an increase
in IL-6 levels following CPB which continued to rise to
reach significance 1–2 days after surgery suggesting rises
in circulating mtDNA may act as a means of predicting
the future inflammatory response and its associated
complications [27].
In order to examine the final component of the triad
of surgical drivers of inflammation we examined
ischaemia-reperfusion in an ex-vivo porcine kidney
model. This translates to an important driver of postop-
erative morbidity in clinical practice, particularly in
patients undergoing cardiac surgery with cardiopulmo-
nary bypass and cardioplegic arrest [18]. Our results
demonstrate that renal IRI leads to an increase in
mtDNA and the pro-inflammatory cytokine IL-6. IL-6
may in turn activate intracellular signaling and stimulate
leukocyte-endothelial interaction leading to leukocyte
migration and tissue damage [28].
Translating mechanism into future targeted anti-
inflammatory therapies
We were able to successfully attenuate TLR9 signaling
through the addition of selective TLR9 antagonists
ODN-2088 in the murine model, leading to a significant
reduction of circulating IL-6 gene expression in vivo. As
such, direct manipulation of this pathway is of potential
therapeutic benefit when considering attenuation of the
inflammatory response. Currently, a Phase I clinical trial
is underway utilizing the TLR-7, − 8 and − 9 antagonist
IMO-8400 to reduce systemic inflammatory drivers in
autoimmune disease [29]. These results will be eagerly
awaited, with the potential for this or similar therapies
to have a role in the treatment for selected cases of post
cardiac surgery SIRS.
It has previously been demonstrated by co-authors
that the antioxidant sulforaphane acts to reduce pro-
inflammatory p38 and nuclear factor-κB activation, sup-
pressing inflammatory cytokine expression in a porcine
CPB model [16]. This study demonstrates that pre-
treatment with sulforaphane may also act through redu-
cing circulating mtDNA release. Although further work
is necessary to address this mechanism in more detail, it
is likely this occurs at least in part secondary to a reduc-
tion in cellular apoptosis combined with intracellular
protection against mitochondrial depolarization and
DNA fragmentation [30]. These results suggest a poten-
tial therapeutic role for treatment with sulforaphane in
the reduction of the systemic inflammatory response to
all components of the triad of cardiac surgical stimuli.
Limitations
A key limitation of this study is that we were not able to
assess the role of TLR9 antagonization in an in vivo
combined CPB-IRI model. Such a model would be most
analogous to human cardiac surgery and therefore re-
quires further exploration in subsequent work. Bigger
sample size experiment with additional parameter of sys-
temic inflammatory reaction such as cardioplegia to
achieve myocardial arrest would be beneficial. Although
outside the scope of this study, other interesting consid-
erations would be to determine the impact of alternative
operative strategies such as off pump cardiac surgery on
pro-inflammatory signaling when compared to conven-
tional CPB. Furthermore, future translational work may
build on the role of anti-TLR9 targeted anti-
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inflammatory therapies in Phase I clinical trials, with the
potential to ultimately reduce the downstream clinical
complications of the post-surgical systemic pro-
inflammatory state.
Conclusions
This study demonstrates a direct link between all com-
ponents of the triad of cardiac surgical stressors and
mitochondrial damage. Subsequent release of circulating
mtDNA activates and signals TLR9, which in turn dir-
ectly stimulates a release of IL-6, leading to endothelial
activation and leukocyte migration. Manipulation of this
pathway by means of a TLR9 antagonist was able to at-
tenuate this response both in vitro and in vivo, and may
provide a future therapeutic target whereby the systemic
inflammatory response to cardiac surgery may be manip-
ulated to improve clinical outcomes.
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